Skip to Main Content
Skip Nav Destination

Issues

Neurodegenerative Diseases 2008, Vol. 5, No. 3-4

Special Section

Neurodegener Dis (2008) 5 (3-4): 109–112. https://doi.org/10.1159/000120416

Paper

Neurodegener Dis (2008) 5 (3-4): 113. https://doi.org/10.1159/000116115

Keynote Address

Neurodegener Dis (2008) 5 (3-4): 114–117. https://doi.org/10.1159/000113678

AD/PD – General Considerations

Neurodegener Dis (2008) 5 (3-4): 118–121. https://doi.org/10.1159/000113679
Neurodegener Dis (2008) 5 (3-4): 122–125. https://doi.org/10.1159/000113680
Neurodegener Dis (2008) 5 (3-4): 126–132. https://doi.org/10.1159/000113681
Neurodegener Dis (2008) 5 (3-4): 133–136. https://doi.org/10.1159/000113682
Neurodegener Dis (2008) 5 (3-4): 137–139. https://doi.org/10.1159/000113683

Beta-Amyloid

Neurodegener Dis (2008) 5 (3-4): 140–142. https://doi.org/10.1159/000113684
Neurodegener Dis (2008) 5 (3-4): 143–145. https://doi.org/10.1159/000113685
Neurodegener Dis (2008) 5 (3-4): 146–148. https://doi.org/10.1159/000113686
Neurodegener Dis (2008) 5 (3-4): 149–152. https://doi.org/10.1159/000113687
Neurodegener Dis (2008) 5 (3-4): 153–156. https://doi.org/10.1159/000113688
Neurodegener Dis (2008) 5 (3-4): 157–159. https://doi.org/10.1159/000113689
Neurodegener Dis (2008) 5 (3-4): 160–162. https://doi.org/10.1159/000113690
Neurodegener Dis (2008) 5 (3-4): 163–165. https://doi.org/10.1159/000113691

Preamyloid

Neurodegener Dis (2008) 5 (3-4): 166–169. https://doi.org/10.1159/000113692
Neurodegener Dis (2008) 5 (3-4): 170–172. https://doi.org/10.1159/000113693
Neurodegener Dis (2008) 5 (3-4): 173–175. https://doi.org/10.1159/000113694

Genetics

Neurodegener Dis (2008) 5 (3-4): 176–178. https://doi.org/10.1159/000113695
Neurodegener Dis (2008) 5 (3-4): 179–181. https://doi.org/10.1159/000113696
Neurodegener Dis (2008) 5 (3-4): 182–185. https://doi.org/10.1159/000113697
Neurodegener Dis (2008) 5 (3-4): 186–189. https://doi.org/10.1159/000113698

Inflammation

Neurodegener Dis (2008) 5 (3-4): 190–193. https://doi.org/10.1159/000113699
Neurodegener Dis (2008) 5 (3-4): 194–196. https://doi.org/10.1159/000113700

Glycosaminoglycans (GAGs)

Neurodegener Dis (2008) 5 (3-4): 197–199. https://doi.org/10.1159/000113701
Neurodegener Dis (2008) 5 (3-4): 200–205. https://doi.org/10.1159/000113702
Neurodegener Dis (2008) 5 (3-4): 206–208. https://doi.org/10.1159/000113703

Various Markers

Neurodegener Dis (2008) 5 (3-4): 209–211. https://doi.org/10.1159/000113704
Neurodegener Dis (2008) 5 (3-4): 212–214. https://doi.org/10.1159/000113705
Neurodegener Dis (2008) 5 (3-4): 215–217. https://doi.org/10.1159/000113706

Alpha-Synuclein

Neurodegener Dis (2008) 5 (3-4): 218–221. https://doi.org/10.1159/000113707
Neurodegener Dis (2008) 5 (3-4): 222–224. https://doi.org/10.1159/000113708

Cholinergic Aspects

Neurodegener Dis (2008) 5 (3-4): 225–227. https://doi.org/10.1159/000113709
Neurodegener Dis (2008) 5 (3-4): 228–231. https://doi.org/10.1159/000113710
Neurodegener Dis (2008) 5 (3-4): 232–236. https://doi.org/10.1159/000113711
Neurodegener Dis (2008) 5 (3-4): 237–240. https://doi.org/10.1159/000113712

Other, Miscellaneous

Neurodegener Dis (2008) 5 (3-4): 241–243. https://doi.org/10.1159/000113713
Neurodegener Dis (2008) 5 (3-4): 244–246. https://doi.org/10.1159/000113714
Neurodegener Dis (2008) 5 (3-4): 247–249. https://doi.org/10.1159/000113715
Neurodegener Dis (2008) 5 (3-4): 250–253. https://doi.org/10.1159/000113716

Aging

Neurodegener Dis (2008) 5 (3-4): 254–256. https://doi.org/10.1159/000113717
Neurodegener Dis (2008) 5 (3-4): 257–260. https://doi.org/10.1159/000113718
Neurodegener Dis (2008) 5 (3-4): 261–263. https://doi.org/10.1159/000113719

Further Section

Neurodegener Dis (2008) 5 (3-4): 264. https://doi.org/10.1159/000120417
Neurodegener Dis (2008) 5 (3-4): 265–266. https://doi.org/10.1159/000120418
Close Modal

or Create an Account

Close Modal
Close Modal